ArticleCaspian journal of internal medicine2016
The effect of serum vitamin D normalization in preventing recurrences of benign paroxysmal positional vertigo: A case-control study.
Article in Caspian journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05748249 ("Randomized, Controlled 3-arm Clinical Study to Evaluate the Efficacy of Supplementation With Vertistop® D and Vertistop® L in Preventing Recurrences of Highly Recurring BPPV), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Randomized, Controlled 3-arm Clinical Study to Evaluate the Efficacy of Supplementation With Vertistop® D and Vertistop® L in Preventing Recurrences of Highly Recurring BPPV (Benign Paroxysmal Positional Vertigo)".
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between vitamin D, vitamin D supplementation and benign paroxysmal positional vertigo: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Prevention of recurrent benign paroxysmal positional vertigo with vitamin D supplementation: a meta-analysis.Journal of neurology · 2022Pooled it
- Effect of vitamin D supplementation on benign paroxysmal positional vertigo recurrence: A meta-analysis.Science progressPooled it
- Effect of Vitamin D Deficiency on Incidence and Relapse of Benign Paroxysmal Positional Vertigo.Iranian journal of otorhinolaryngology · 2026Article
- Serum Otoconin-90 and Otolin-1 Concentrations in Benign Paroxysmal Positional Vertigo.Biomolecules · 2024Article
- Review
- Vitamin D supplementation in preventing the recurrence of benign paroxysmal positional vertigo.Laryngoscope investigative otolaryngology · 2024Article
- Article
- Prevention of Recurrent Benign Paroxysmal Positional Vertigo: The Role of Combined Supplementation with Vitamin D and Antioxidants.Audiology research · 2022Article
- Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women.Frontiers in neurology · 2020Review
- Serum levels of 25-hydroxy vitamin D correlate with idiopathic benign paroxysmal positional vertigo.Bioscience reports · 2019Article
- A Relationship Between Blood Levels of Otolin-1 and Vitamin D.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2018Article
- Analysis of effect of 1α-hydroxyvitamin D3 on benign paroxysmal positional vertigo and risk factors.Experimental and therapeutic medicine · 2018Article
- Assessment of Bone Metabolism in Male Patients With Benign Paroxysmal Positional Vertigo.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign paroxysmal positional vertigo (BPPV) is a condition with recurrent attacks in a significant proportion of patients. The present case- control study was conducted to assess the influence of serum vitamin D normalization on recurrent attacks of vitamin D deficient patients.
methodsDiagnosis of BPPV was made based on history and clinical examination and exclusion of other conditions. Serum 25-hydroxy vitamin D (25-OHD) was measured using ELISA method and a levels of < 20 ng/ml was considered a deficiency of vitamin D. Inclusion criteria were as follows: history of recurrent attacks and serum 25-OHD<20.ng/ml. While the patients with history of trauma, surgery and chronic systemic diseases were excluded. The patients were classified into two groups: treatment and control, intermittently. Both groups received Epley rehabilitation therapy one session per week for 4 weeks but the treatment group received an additional supplement of 50.000 IU of vitamin D (cholecalciferol) weekly for two months to achieve serum 25-OHD ≥ 30 ng/ml and the study patients were followed-up for 6 months.
resultsTwenty-seven patients were allocated to each group. At baseline, serum 25-OHD was similar (10.7±2.3 vs 11.41±1.9, P=0.23). At month 2, serum 25-OHD in the treatment group increased significantly to ≥ 30 ng/ ml, whereas serum 25-OHD in the control group remained unchanged (34.2±3.3 vs 10.6 10.6±2.2 ng/ml, P=0.001). During the follow-up period, attacks of BPPV in the treatment group decreased significantly compared with the control group (14.8% vs 96.3% OR= 0.18, P=0.001).
conclusionThe findings of this study indicate that the normalization of serum vitamin D significantly reduces BPPV recurrences.
Indexed as
Identifiers
27757201PMC5062174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.